FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - June 27, 2025 442 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARANOTE study Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR ΚΑΡΚΙΝΟΣ ΧΟΛΗΔΟΧΟΥ ΚΥΣΤΕΩΣ March 8, 2019 Many Older Adults Screened Unnecessarily for Common Cancers August 27, 2020 Study Shows Experimental Screening Test Can Detect Endometrial and Ovarian Cancers May 2, 2018 New Study Says At-Home Cancer Care May Lead to Fewer Hospitalizations... May 20, 2021 Load more HOT NEWS Pazopanib Shows Promise for Children, Adults with Soft Tissue Sarcomas Adding Pembrolizumab To Preoperative Radiotherapy and Surgery Improves DFS for Patients... Superior Prognostic Accuracy of Integrated 15-GEP/PRAME Classifier Over 15-GEP Alone in... First-Line Treatment with Atezolizumab Associated with Improved OS in Patients with...
